Publications by authors named "E Bomassi"
Introduction: Heart rate (HR) is often elevated in cats with cardiomyopathies (CMPs). Pharmacologic modulation of HR may reduce cardiac morbidity and mortality.
Objectives: To investigate the effects of cilobradine vs.
Introduction/objectives: Ebstein's anomaly (EA) is a congenital heart disease characterized by apical displacement of the tricuspid valve leaflets in the right ventricle. The objective of this retrospective study was to investigate the signalment, clinical features, echocardiographic findings, and outcome of dogs with EA.
Animals, Materials And Methods: Medical records of 40 dogs with EA were reviewed.
Article Synopsis
- The EPIC study monitored dogs with myxomatous mitral valve disease (MMVD) to observe how they develop congestive heart failure (CHF).
- It compared clinical and radiographic changes in dogs that developed CHF against those that did not, analyzing factors like heart rate and respiratory rate.
- Key findings showed that dogs approaching CHF had significant increases in respiratory rates and heart rates, along with decreases in body weight and temperature, highlighting respiratory rates as crucial indicators of CHF onset.
Background: Heart disease is an important cause of morbidity and mortality in cats, but there is limited evidence of the benefit of any medication.
Hypothesis: The angiotensin-converting enzyme inhibitor benazepril would delay the time to treatment failure in cats with heart disease of various etiologies.
Animals: One hundred fifty-one client-owned cats.
Background: Changes in clinical variables associated with the administration of pimobendan to dogs with preclinical myxomatous mitral valve disease (MMVD) and cardiomegaly have not been described.
Objectives: To investigate the effect of pimobendan on clinical variables and the relationship between a change in heart size and the time to congestive heart failure (CHF) or cardiac-related death (CRD) in dogs with MMVD and cardiomegaly. To determine whether pimobendan-treated dogs differ from dogs receiving placebo at onset of CHF.